US · PACB
Pacific Biosciences of California, Inc.
- Sector
- Healthcare · Medical - Devices
- Headquarters
- Menlo Park, CA 94025
- Website
- pacb.com
Price · as of 2025-12-31
$1.60
Market cap 507.2M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $23.71 | +1,381.88% |
| Intrinsic Value(DCF) | $0.65 | -59.38% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $3.61 | $269.15 | $8,496.92 | $0.00 | $0.00 |
| 2012 | $2.37 | $25.36 | $0.00 | $0.00 | $23.83 |
| 2013 | $6.67 | $28.41 | $0.00 | $0.00 | $0.00 |
| 2014 | $5.86 | $37.25 | $11.19 | $0.00 | $0.00 |
| 2015 | $7.83 | $33.01 | $179.40 | $0.00 | $0.00 |
| 2016 | $4.80 | $23.70 | $1.78 | $0.00 | $0.00 |
| 2017 | $2.78 | $24.19 | $0.00 | $0.00 | $0.00 |
| 2018 | $7.29 | $27.21 | $0.00 | $0.00 | $5.31 |
| 2019 | $3.95 | $25.75 | $0.00 | $0.00 | $0.00 |
| 2020 | $33.89 | $51.97 | $0.95 | $2.92 | $0.00 |
| 2021 | $9.90 | $55.30 | $2.07 | $0.00 | $0.00 |
| 2022 | $8.30 | $23.99 | $0.36 | $0.00 | $0.00 |
| 2023 | $4.43 | $28.32 | $1.88 | $0.00 | $0.00 |
| 2024 | $1.33 | $30.40 | $0.00 | $0.00 | $15.87 |
| 2025 | $1.62 | $23.71 | $0.00 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Pacific Biosciences of California, Inc.'s (PACB) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $23.71
- Current price
- $1.60
- AI upside
- +1,381.88%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$0.65
-59.38% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| PACB | Pacific Biosciences of Ca… | $1.60 | 507.2M | +1,382% | -59% | — | — | -0.89 | 90.85 | 3.04 | -28.24 | -1.27 | -1.48 | 31.67% | -348.46% | -341.47% | -213.45% | -87.50% | -53.45% | 141.98 | -80.18 | 6.89 | 5.79 | -14.03 | 7009.00% | 389.00% | -4633.00% | -23.44% | -2.04 | -17.88% | 0.00% | 0.00% | 28.22% | -1.73 | -8.48 | 6.04 | -1.28 |
| AVNS | Avanos Medical, Inc. | $14.10 | 654.51M | +97% | -60% | -93% | — | -8.90 | 0.83 | 0.93 | -20.72 | — | 2.44 | 49.77% | -8.78% | -9.68% | -9.07% | -7.21% | -6.54% | 0.17 | -15.40 | 2.15 | 1.17 | -1.18 | -8288.00% | 195.00% | -4801.00% | 6.64% | 0.45 | 5.05% | 0.00% | 0.00% | 3.58% | -11.17 | 15.96 | 0.98 | 0.98 |
| BFLY | Butterfly Network, Inc. | $3.79 | 957.36M | +668% | -29% | — | — | -12.35 | 4.85 | 9.75 | -12.15 | — | 5.05 | 46.85% | -88.53% | -78.95% | -42.25% | -104.05% | -27.89% | 0.09 | -58.00 | 3.83 | 2.72 | 1.97 | -882.00% | 1896.00% | -6386.00% | -1.69% | -0.20 | -19.32% | 0.00% | 0.00% | 7.02% | -9.47 | -51.01 | 8.39 | 1.64 |
| DNA | Ginkgo Bioworks Holdings,… | $6.75 | 408.98M | +75% | -49% | — | +1,219% | -1.25 | 0.77 | 2.30 | -1.51 | — | 0.87 | 81.48% | -185.29% | -183.81% | -51.08% | -55.89% | -25.05% | 0.82 | — | 4.92 | 4.65 | -0.98 | -4649.00% | -2506.00% | -5323.00% | -45.71% | -1.78 | -31.77% | 0.00% | 0.00% | 0.00% | -1.22 | -2.16 | 2.27 | -7.68 |
| DRIO | DarioHealth Corp. | $11.97 | 80.9M | +162% | -51% | — | — | -22.91 | 13.60 | 36.23 | -19.50 | — | -234.90 | 49.06% | -213.55% | -158.09% | -65.68% | -88.81% | -39.71% | 0.42 | -601.50 | 2.44 | 2.03 | -0.05 | -6839.00% | 3286.00% | 2499.00% | -3.95% | -2.32 | -62.10% | 0.00% | 0.00% | 0.00% | -16.99 | -25.36 | 36.29 | 6.81 |
| FLGT | Fulgent Genetics, Inc. | $15.33 | 473.89M | +1,814% | -46% | +66% | — | -7.09 | 0.39 | 1.35 | -2.21 | -17.85 | 0.43 | 40.56% | -19.10% | -18.75% | -5.49% | -6.54% | -5.07% | 0.00 | -821.75 | 6.48 | 4.95 | 1.08 | 3972.00% | 1383.00% | 54509.00% | -28.42% | -1.20 | -14.97% | 0.00% | 0.00% | 3.19% | -1.65 | -0.82 | 0.31 | 3.63 |
| IART | Integra LifeSciences Hold… | $11.38 | 886.41M | +457% | -63% | — | — | -1.55 | 0.77 | 0.49 | -1.58 | -0.02 | -1.13 | 51.69% | -30.17% | -31.58% | -39.90% | -21.27% | -13.52% | 0.21 | -5.72 | 2.54 | 1.19 | 0.04 | 736120.00% | 153.00% | -22439.00% | -3.88% | 0.11 | -1.46% | 0.00% | 0.00% | 219.53% | -1.53 | -24.24 | 0.46 | 0.59 |
| IOVA | Iovance Biotherapeutics, … | $3.86 | 1.28B | +666% | -61% | — | — | -3.46 | 1.94 | 5.14 | -3.10 | — | 3.23 | 97.23% | -153.08% | -148.38% | -55.50% | -89.67% | -42.88% | 0.07 | — | 3.20 | 2.74 | 0.32 | -1484.00% | 6060.00% | -764.00% | -24.83% | -2.19 | -75.14% | 0.00% | 0.00% | 4.22% | -2.74 | -3.29 | 4.20 | -1.24 |
| OFIX | Orthofix Medical Inc. | $13.53 | 535.78M | +193% | -60% | — | — | — | 1.18 | 0.65 | -30.45 | — | 2.92 | 67.09% | -8.33% | -11.21% | 0.00% | -11.44% | 0.00% | 0.51 | -3.92 | 2.45 | 1.28 | -6.59 | -3091.00% | 285.00% | -8592.00% | -0.24% | 0.20 | -0.21% | 0.00% | — | 0.00% | -9.94 | -532.03 | 0.83 | 1.24 |
| POM | POMDOCTOR Ltd | $0.24 | 25.85M | — | — | — | — | — | — | — | — | — | — | 13.92% | -7.53% | -41.85% | 1.70% | 1.46% | -66.41% | -0.19 | -1.99 | 0.21 | 0.13 | -17.86 | -163.00% | 1237.00% | -6478.00% | — | -0.09 | 0.91% | — | 0.00% | — | — | — | — | — |
| SIBN | SI-BONE, Inc. | $15.52 | 673.43M | +222% | +44% | -88% | — | -36.13 | 3.85 | 3.40 | -49.18 | — | 3.85 | 79.57% | -11.11% | -9.41% | -10.97% | -52.40% | -8.06% | 0.01 | -4.23 | 8.55 | 7.03 | 3.77 | -4133.00% | 2019.00% | -6035.00% | -1.33% | -0.03 | -21.33% | 0.00% | 0.00% | 6.39% | -24.02 | -59.01 | 2.67 | 5.57 |
About Pacific Biosciences of California, Inc.
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a development and commercialization agreement with Invitae Corporation. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
- CEO
- Christian O. Henry
- Employees
- 575
- Beta
- 2.28
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($0.65 ÷ $1.60) − 1 = -59.38% (DCF, example).